TrialThe Journal of infectious diseases2023

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.

Javier Díez-Domingo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.